- Conditions
- Relapsing Remitting Multiple Sclerosis
- Interventions
- Cyclophosphamide/Glatiramer acetate
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 70 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- Alemtuzumab, Interferon beta-1a
- Biological
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 581 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 36
- States / cities
- Cullman, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 31 more
- Conditions
- Multiple Sclerosis
- Interventions
- Ofatumumab 3mg, Ofatumumab 30mg, Ofatumumab 60mg, Placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 232 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 16
- States / cities
- Cullman, Alabama • Fullerton, California • Fairfield, Connecticut + 13 more
- Conditions
- Multiple Sclerosis
- Interventions
- Avonex® monotherapy (6.0 MIU administered i.m. each week)
- Drug
- Lead sponsor
- State University of New York at Buffalo
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Multiple Sclerosis
- Interventions
- [18F]Florbetapir PET imaging
- Drug
- Lead sponsor
- Institute for Neurodegenerative Disorders
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Relapsing-remitting Multiple Sclerosis (RRMS)
- Interventions
- Ocrelizumab (US), Ocrelizumab (EU), ABP 692
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 152 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 27
- States / cities
- Mobile, Alabama • Scottsdale, Arizona • Carlsbad, California + 24 more
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- Not listed
- Lead sponsor
- Mallinckrodt
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 38
- States / cities
- Homewood, Alabama • Tucson, Arizona • Colorado Springs, Colorado + 35 more
- Conditions
- Relapsing Remitting Multiple Sclerosis
- Interventions
- Simethicone, Loperamide, Peanut Butter
- Drug · Other
- Lead sponsor
- Rocky Mountain MS Research Group, LLC
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Relapse-Remitting Multiple Sclerosis
- Interventions
- glatiramer acetate 20 mg, glatiramer acetate 40 mg
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2005
- U.S. locations
- 20
- States / cities
- La Jolla, California • Oceanside, California • Atlanta, Georgia + 17 more
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- Methotrexate, IV methylprednisolone
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2007
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Multiple Sclerosis
- Interventions
- Blood Draw
- Other
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2017
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Relapsing-Remitting Multiple Sclerosis
- Interventions
- natalizumab, fingolimod
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 111 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2016
- U.S. locations
- 12
- States / cities
- Aurora, Colorado • Colorado Springs, Colorado • Port Charlotte, Florida + 9 more
- Conditions
- Relapsing-Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
- Interventions
- natalizumab, standard of care
- Drug · Other
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 12
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Berkeley, California + 9 more
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- ACTOS (Pioglitazone)
- Drug
- Lead sponsor
- University of Illinois at Chicago
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2005
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Relapsing-Remitting Multiple Sclerosis
- Interventions
- Donepezil HCI (drug)
- Drug
- Lead sponsor
- Neurognostics
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Multiple Sclerosis, RRMS, Relapsing Remitting MS
- Interventions
- HP 13C pyruvate injection, MRI Scanner
- Drug · Device
- Lead sponsor
- Ari Green
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Relapsing-Remitting Multiple Sclerosis
- Interventions
- BG00012, Placebo
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 1,234 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 39
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • San Francisco, California + 36 more
- Conditions
- Multiple Sclerosis
- Interventions
- Fingolimod 1.25 mg, Fingolimod 0.5 mg, Interferon β-1a 30 µg
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 1,292 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 35
- States / cities
- Cullman, Alabama • Phoenix, Arizona • Oceanside, California + 31 more
- Conditions
- Multiple Sclerosis
- Interventions
- Laquinimod, Placebo
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 2,199 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 32
- States / cities
- Cullman, Alabama • Sun City, Arizona • Tucson, Arizona + 29 more
- Conditions
- Multiple Sclerosis
- Interventions
- Ponesimod 10 mg, Ponesimod 20 mg, Ponesimod 40 mg
- Drug
- Lead sponsor
- Actelion
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 353 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2023
- U.S. locations
- 16
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Palo Alto, California + 13 more
- Conditions
- Pediatric Multiple Sclerosis
- Interventions
- Not listed
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 3 Years to 21 Years
- Enrollment
- 1,276 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2018
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • San Bernardino, California • San Francisco, California + 13 more
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- Not listed
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5,448 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- Relapsing-Remitting Multiple Sclerosis
- Interventions
- GA 20 mg/mL, GA 40 mg/mL
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 209 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 35
- States / cities
- Cullman, Alabama • Gilbert, Arizona • Phoenix, Arizona + 31 more
- Conditions
- Relapsing-Remitting Multiple Sclerosis
- Interventions
- BG00012, Placebo, Glatiramer Acetate
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 1,417 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 72
- States / cities
- Birmingham, Alabama • Cullman, Alabama • Huntsville, Alabama + 69 more